# Adjustment of Aminoglycoside Dosing Based on Peak Serum Concentration and Bacterial Minimal Inhibitory Concentration

> **NCT05618457** · NA · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 151 (estimated)

## Conditions studied

- Aminoglycoside Dosing Based on PK/PD Characteristics

## Interventions

- **DRUG:** Aminoglycoside dose adjustment

## Key facts

- **NCT ID:** NCT05618457
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 151 (ESTIMATED)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618457, "Adjustment of Aminoglycoside Dosing Based on Peak Serum Concentration and Bacterial Minimal Inhibitory Concentration". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05618457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*